Doxazosin

DEA Class;  Rx

Common Brand Names; Cardura, Cardura XL

Hypersensitivity to doxazosin or other quinazolines

• Dizziness (5-19%)
• Fatigue (8-12%)
• Headache (6-10%)
• Vertigo (7%)
• Upper respiratory tract infection (URTI) (5%)
• Edema (3-4%)
• Rhinitis (3%)
• Dyspnea (1-3%)
• Abdominal pain (2%)
• Hypotension (1-2%)
• Nausea (1-2%)
• Orthostatic hypotension (dose related) (0.3-2%)
• Anxiety (1%)
• Palpitations (1%)
• Autonomic Nervous System: Priapism
• Cardiovascular System: Cerebrovascular accidents, dizziness postural, myocardial infarction
• Central and Peripheral Nervous System: Hypoesthesia, paresthesia
• Endocrine System: Gynecomastia
• Gastrointestinal System: Gastrointestinal obstruction, vomiting
• General Body System: Fatigue, hot flushes, malaise
• Heart Rate/Rhythm: Bradycardia, cardiac arrhythmias
• Hematopoietic: Leukopenia, purpura, thrombocytopenia
• Liver/Biliary System: Abnormal liver function tests, hepatitis, hepatitis cholestatic, jaundice

Use with caution in liver disease or recent cerebrovascular accident (CVA)

Rule out prostate cancer before initiating therapy

May cause first-dose syncope or sudden loss of consciousness

Risk of orthostatic hypotension (dose dependent)

Potential for hypotension, dry mouth, and urinary complications in elderly

Priapism (painful penile erection, sustained for hours and unrelieved by sexual intercourse or masturbation) rarely reported (probably less frequently than once in every several thousand patients), with alpha-1 antagonists, including doxazosin; because condition can lead to permanent impotence if not promptly treated, patients must be advised about seriousness of condition

Concomitant use of other antihypertensives (additive hypotensive effects)

Extended-release form not indicated for hypertension

Concomitant administration of immediate-release form with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension

Not indicated for use in females or for the treatment of hypertension; the limited available data in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage

Present in human milk; there is no information on effects on breastfed infant or effects on milk production

Doxazosin mesylate